




2022 BIO TAIPEI

Investment Guide



臺北市政府產業發展局
Department of Economic Development
Taipei City Government





Taipei Highlights

271.8 km²

Surface Area

2.52 million

Population

1.27 million

Working Population

US\$415.9 billion

Annual Total Revenue

237,401

Number of Businesses

100%

Fiber Coverage Rate

Status of Taipei's Biotech Industry

Taipei has a complete industrial infrastructure, from venture capital, R&D, incubators, and talent cultivation institutions, through to industrial supply networks and clinical markets

US\$7.68 Billions
Annual Revenue



8
Medical Centers



11
Bio Accelerators

555
Number of Companies



30
Research
Institutions &
Colleges



214
Venture Capital
Companies

38,213
Number of Employees



19
Bio Incubators

Future Industrial Space

4+1 Industrial Park Project

Shezidao Eco-project
Launch Date: 2025

Beitou Shilin Science Park
Launch Date: 2019

Innovation Park of Yuanshan Expo venue
Launch Date: 2017

Neihu Technology Park Version 2.0
Launch Date: 2016

Nangang Biotechnology Cluster
Launch Date: 2016

Industries of the Future Reserved for Department

Smart Health Care
Industry Digital
Technology Service
Industry

ICT Industry
Biotechnology
Industry Startups

Biotechnology/POP Music
Startups/Software Exhibition
Industry

- Promote a next-generation industrial park
- Connect industrial clusters
- Redefine urban industrial land use

TAIPEI CITY

Taipei Bioinnovation Park


2023 Grand Open



17 floors
of the building

3 minutes

walk to MRT Nangang Station and High Speed Rail Station



Total Area

94,460.49 m²

Industrial Space

labs, offices, pilot plants
38,701.3 m²

Incubators

15,2630.46 m²

Complete Value Chain of Taipei Biotechnology Industry

Step 1

Basic Research

Step 2

Preclinical Development

Step 3


Clinical Trial Review(IND)

Step 4

Clinical Trial Prototyping

Step 5

New Drug Registration(NDA)



The Biotech Hub to Asia

Contact Us

Website <https://www.biodriven.taipei/en/index.aspx>

Location 2F, North Wing, No. 1, City Hall Road, Xinyi District, Taipei City 11008, Taiwan

Hotline 886 02-27208889 ext 6584

Email biotaipei@cpc.tw



ito
invest taipei



invest.taipei



invest.taipei

iINVEST
tAIPEI
OFFICE

One Stop Service
for Landing Taipei



886-2-2757-4519
886-2-2757-4518



info@invest.taipei



2F, North Wing, No. 1, City Hall Road, Xinyi
District, Taipei City 11008, Taiwan



Far East Bio-Tec Co., Ltd.

Major Fields

**New Drugs Development,
Antiviral Remedy,
Nutraceuticals.**

Website

www.febico.com

Contact

Shawn Y.H. Chen

Address

**Room A, 13FL, No.3, Yuan
Chiu Street, Nan-Gang
District, Taipei, Taiwan,
R.O.C.**

FEBICO (Far East Bio-Tec. Co., Ltd.) was established in 1976 by our founder Mr. C. C. Chiueh. Our current operational targets are classified as four main axes : "Nutrition Health Care", "Biomedical Reagents", "New Drug Development" and "Green Energy Environmental Protection". We have the following plans and expectations for the future development: 1. The antiviral technology on influenza virus, enterovirus, hepatitis B virus, SARS-CoV2 and Ebola virus had been further applied on epidemic prevention product, medical device, and new drugs developments, 2. New drug development of reversal liver fibrosis. 3. New drug development of treatment of chronic hepatitis B.



Bened Biomedical Co.,Ltd.

Major Fields

Functional probiotic raw material supply.
Private label service.
Customized probiotic formulation (containing our own patented strains).
Clinical research collaboration.

Website

www.benedbiomed.com

Address

**2F-2, No.129, Section 2,
Zhongshan North Road,
Taipei City 104, Taiwan**

Contact

Serena Tsai
Program Manager
serena@benedbiomed.com

Founded in 2015 in Taipei, Taiwan, Bened Biomedical Co., Ltd. is a global leader of microbiome-based products. The company uses its own patented strains to develop microbiome-based therapy for neuropsychological, aging-related, allergic, immunological, and metabolic disorders. Several milestones have been completed to demonstrate the efficacy and safety of Lactobacillus plantarum PS128®, through a series of successful clinical studies targeting either patients or healthy people. We continue to build up a pipeline of clinical studies including research on stress, anxiety, Autism, Parkinson’s disorder, etc. Based on past research and commercial performance, in 2020 Bened was named as one of the Top 10 key Players in Psychobiotic Supplements Market by Future Market Insights. Our mission is to develop best-of-breed psychobiotics to effectively prevent and treat neuropsychological disorders for the global community. The name “Bened,” derived from the Latin word for “full of blessings,” affirms the brand’s hope to bless the world through its products.



BRIM Biotechnology, Inc.

Major Fields

Regenerative Medicines, Dry Eye Syndrome, PEDF Technology Platform

Website

www.brimbiotech.com/en/

Contact

Yichun Maria Chen
VP of Business Development
yichun.chen@brimbiotech.com

Address

**No. 1, Alley 30, Lan3 358,
Ruiguang Rd., Neihu Dist.,
Taipei 11492, Taiwan**

BRIM Biotechnology, Inc. applies integrated and efficient translational science to develop new treatments that help combat and cure disease. Our extensive experience and successful track record of translating discovery research to the clinic enables us to find and incubate high-potential novel drug candidates through our unique drug development engine to deliver partner-ready clinical assets.

The key drug candidate is a synthetic peptide composed of 29 amino acids derived from a multi-functional protein, Pigment Epithelium-Derived Factor (PEDF), with neurotrophic and anti-inflammation properties. The functional domain of PEDF chosen to generate PEDF-derived short peptides (PDSP) also has a unique mechanism of action that can promote the “stemness” of certain types of stem cells, including mesenchymal stem cells. These properties allow PDSPs to be applied to a broad range of diseases that require faster tissue repair.

BRIM currently has 3 first-in-class, disease-modifying lead assets developed from the stem cell regenerative PDSP platform, i.e. BRM421 for Dry Eye Syndrome (DES), BRM424 for Neurotrophic Keratitis, and BRM521 for osteoarthritis.

Particularly in the eyes, this unique mechanism of action stimulates the proliferation and differentiation of corneal limbal stem cells, which as a result, speeds up corneal repair and heals ocular wounds in DES patients. BRM421 has shown promising clinical outcomes in two phase 2 studies with superior safety profiles. With encouraging efficacy and favorable safety profiles, BRM421 may enter a phase 3 study by the end of 2022.



Instant NanoBiosensors Co., Ltd.

Major Fields

**Biomarker research/Detection and commercialization.
Technology out-licensing & OEM of
Neurological Disease Biomarker
Testing.**

Website

www.instantnano.com

Contact

**Tony Chung
CEO & Co-founder
cmo@instantnano.com**

Address

**3F, C Building, National
Biotechnology Research Park,
R.O.C (Taiwan)**

Instant NanoBiosensors is a life sciences company that has developed ultra-sensitive digital immunoassay platforms, Light Sensing Biomarker Analyzer, based on patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies. Only 20µL of blood is needed, and the result can be known in minutes with three simple steps. The simple and ultra-sensitive blood-based biomarker platform that could pinpoint the neurological disease process well before any cognitive symptoms would allow physicians to give any potential disease-slowing therapy at a very early point in the neurological disease process. We are looking for potential partners with three aspects:

- 1. U.S. distribution partners: To deliver our devices and consumables to customers in the life science market.**
- 2. Out-licensing & OEM: INB provides a highly flexible platform focusing on molecular and biomarker tests. We hope to build more strategic partnership with international associates, especially U.S. biopharma and biotech companies, while assisting the development and manufacture of products to meet the demands of laboratory tests in life science and diagnosis in a cost-effective manner.**
- 3. Advancing biomedical research to commercialize: We provide the analytical service to our customers including academic institutes, vaccine companies, pharma companies and biotech companies for the commercialization of lab-based research.**



QT Medical

QT Medical, Inc.

Major Fields

Medical 12-Lead ECG System, including device manufacturing, software and algorithm development.

Website

www.qtmedical.com

Contact

Lucy Lin
Deputy Director of Sales & Marketing
sn.lin@qtmedical.com

Address

1360 Valley Vista Dr., Suite 203, Diamond Bar, CA 91765, USA

QT Medical is a medtech company with a focus on high quality 12-lead diagnostic electrocardiogram (ECG) for use by healthcare professionals and patients. Cleared by the FDA, TFDA, and CE marked, PCA 500 is the world's most compact 12-lead ECG system. With its simplicity, ease of use, mobile technology and cloud management, PCA 500 brings hospital-grade ECG to homes, and enables doctors to make informed decisions anywhere, anytime. Powered by advanced AI diagnostics, QT Medical will revolutionize cardiac care in the 21st century for millions of patients.



TaiHao Medical Inc.

Major Fields

Medical image (SaMD) / AI solution on medical image / Digital Health Smart healthcare / Medical software Medical device Diagnostics & analysis.

Website

www.taihaomed.com

Contact

Julia Chang
Sales Director
juliachang@taihaomed.com

Address

**6F.-1, No. 100, Sec. 2,
Heping E. Rd., Da'an Dist.,
Taipei City 10663,
Taiwan**

TaiHao Medical Inc. is an artificial intelligence company founded in 2013 that focusing on computer-aided detection and diagnosis. Headquarter is in Taipei, Taiwan. Our team consists of experts from multidisciplinary domains including artificial intelligence, biomedical engineering and medicine. The image processing methodology with artificial intelligence is evaluated to be helpful in assisting physicians in breast cancer detection. The available products including "BR-Viewer", "BR-FHUS Smart System" and BU-CAD are focusing on breast screening to meet the upcoming requirements. Either for images from handheld or ABUS ultrasound, the corresponding computer-aided system is ready. Eventually, we aim at being the leader of medical software with whole body health care in the world.